ARS Pharmaceuticals SPRY Income Statement (2020-2026)

NASDAQ SPRY
$3.61 +0.46 (+14.60%)
As of: Nov 10, 2026 · 1:13 PM EST
Reported Financials

ARS Pharmaceuticals Quarterly Income Statement

Periods 27 quarters
Latest Sep 2026

ARS Pharmaceuticals reported revenue of $37.71M and net income of -$34.17M for the quarter ended Sep 2026, up 16.0% year over year. This income statement covers 27 quarters of results from Mar 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.05M0.66M0.46M0.19M0.02M0.01M0.50M2.07M86.58M7.97M15.72M32.50M28.09M22.68M33.66M37.71M
Cost of RevenueCost of Rev
0.11M0.87M1.09M4.98M8.19M6.15M6.29M12.85M10.10M
Gross Profit
0.50M1.96M85.72M6.88M10.73M24.31M21.93M16.40M20.81M27.61M
Operating items
Research & DevelopmentR&D
-25.36M5.42M4.35M3.89M4.71M6.55M7.31M3.00M3.40M5.23M6.90M4.42M3.03M2.95M4.04M2.75M3.44M4.34M4.70M18.26M
Selling, General & AdministrativeSG&A
-15.76M2.34M2.46M2.93M10.73M12.18M13.31M14.98M6.82M7.96M8.94M19.28M35.49M41.10M54.31M74.75M59.96M72.20M77.58M43.52M
Other Operating ExpensesOther Opex
0.80M0.11M0.87M1.09M4.98M8.19M6.15M6.29M12.85M10.10M
Operating ExpensesOpex
-41.12M7.76M6.81M6.82M15.44M18.73M20.61M17.98M10.23M13.19M15.84M23.82M39.38M45.15M63.33M85.69M69.55M82.83M95.12M71.88M
Operating IncomeOp. Inc
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-1.09M0.95M
Other Non Operating IncomeOther Non Op Inc.
-0.15M-0.08M0.05M1.15M3.75M3.23M3.11M3.06M2.90M2.82M2.62M3.03M3.24M2.73M2.04M2.66M2.44M2.48M2.55M
Net income details
EBIT
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
EBT
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
Income After Tax
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
Income from Continuing OperationsIncome (Continuing)
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
Consolidated Net IncomeConsol Net Inc.
46.62M-7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M-41.47M-60.15M-61.47M-34.17M
Income towards Parent CompanyParent Net Inc
45.78M-7.25M-6.42M-6.58M-14.43M-14.96M-17.37M-14.87M-7.17M-10.29M-12.52M-19.13M49.93M-33.94M-44.88M-51.15M-41.32M-60.62M-62.34M-35.59M
Net Income towards Common StockholdersNet Income
45.78M-7.25M-6.42M-6.58M-14.43M-14.96M-17.37M-14.87M-7.17M-10.29M-12.52M-19.13M49.93M-33.94M-44.88M-51.15M-41.32M-60.62M-62.34M-35.59M
Additional items
EPS (Basic)
1.31-0.21-0.18-0.19-0.36-0.16-0.18-0.16-0.08-0.11-0.13-0.200.52-0.35-0.46-0.52-0.42-0.61-0.63-0.36
EPS (Diluted)
1.59-0.24-0.21-0.19-0.36-0.16-0.18-0.16-0.08-0.11-0.13-0.200.49-0.35-0.46-0.52-0.42-0.61-0.63-0.36
Shares Outstanding
34.93M35.11M35.13M35.46M39.96M94.23M94.91M95.58M95.22M96.49M96.83M97.03M96.94M98.06M98.36M98.81M98.57M99.30M99.31M99.69M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
28.87M30.37M30.61M35.46M39.96M94.23M94.91M95.58M95.22M96.49M96.83M97.03M102.39M98.06M98.36M98.81M98.57M99.30M99.31M99.69M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
35.11M35.12M35.17M35.88M39.96M94.45M95.32M95.80M96.41M96.57M96.94M97.15M97.95M98.13M98.70M98.84M99.29M99.30M99.44M100.53M
EBITDA
46.83M-6.89M-6.38M-6.62M-15.43M-18.69M-20.58M-17.88M-10.23M-13.18M-15.32M-21.65M47.23M-36.90M-47.34M-52.80M-41.05M-59.75M-61.05M-33.76M

ARS Pharmaceuticals Income Statement API

Pull ARS Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SPRY&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY